Related Experiment Video

Updated: Jun 14, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Unveiling EFNB2 as a Key Player in Sorafenib Resistance: Insights from Bioinformatics Analysis and Functional

Junli Pan1, Quanxi Li1, Junli Zhu2

  • 1Department of General Surgery, The Second People's Hospital of Lianyungang, Lianyungang, 222000, China.

Biochemical Genetics
|August 30, 2024
PubMed

Insights

Identifying new targets is crucial for overcoming sorafenib resistance in hepatocellular carcinoma (HCC). This study highlights EFNB2 as a key player in HCC drug resistance, offering a potential therapeutic target.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Cancer Drug Resistance Mechanisms
  • Bioinformatics and Molecular Biology

Background:

  • Sorafenib is a standard treatment for advanced hepatocellular carcinoma (HCC), but resistance significantly limits its efficacy.
  • Identifying novel molecular targets is essential to overcome sorafenib resistance and improve patient outcomes in HCC.
  • High-throughput screening and bioinformatics analyses are powerful tools for discovering new therapeutic targets in cancer.

Purpose of the Study:

  • To identify novel molecular targets associated with sorafenib resistance in hepatocellular carcinoma (HCC) using bioinformatics and in vitro validation.
  • To investigate the role of identified genes, particularly EFNB2, in the development and progression of sorafenib resistance in HCC.
  • To evaluate the therapeutic potential of targeting EFNB2 to sensitize HCC cells to sorafenib treatment.

Main Methods:

  • Utilized public Gene Expression Omnibus (GEO) datasets (GSE140202, GSE143233, GSE182593) for bioinformatics analysis.
  • Identified differentially expressed genes (DEGs) and constructed protein-protein interaction (PPI) networks to pinpoint hub genes.
  • Performed in vitro experiments using HCC cell lines to validate the role of EFNB2 in sorafenib resistance, including gene silencing and overexpression studies.

Main Results:

  • Identified 20 common differentially expressed genes (DEGs) across three GEO datasets, with functional enrichment suggesting roles in drug resistance pathways.
  • Pinpointed 14 hub genes from the PPI network, with EFNB2 identified as a highly connected gene.
  • Demonstrated that EFNB2 is upregulated in sorafenib-resistant HCC cells and that its suppression sensitizes cells to sorafenib, increasing apoptosis and inhibiting epithelial-mesenchymal transition (EMT).

Conclusions:

  • EFNB2 is a significant contributor to sorafenib resistance in HCC, potentially by modulating apoptosis and EMT.
  • Targeting EFNB2 presents a promising strategy to overcome sorafenib resistance in hepatocellular carcinoma.
  • This study identified 14 potential genes involved in HCC sorafenib resistance, with EFNB2 as a key therapeutic target.
Keywords:
Bioinformatics analysisEFNB2HCCHub genesSorafenib resistance

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K